In a child aged 5‑15 with acute rheumatic fever following a recent group A streptococcal throat infection, is anti‑hyaluronidase therapy indicated and what is the recommended treatment?

Anti-Hyaluronidase Testing in Acute Rheumatic Fever

Anti-hyaluronidase testing is a diagnostic laboratory marker, not a therapy—there is no such thing as "anti-hyaluronidase therapy" for acute rheumatic fever. The question appears to conflate a serologic test with treatment. The management of acute rheumatic fever in a child aged 5–15 following group A streptococcal pharyngitis centers on eradicating residual streptococci, treating inflammatory manifestations, and initiating long-term secondary prophylaxis to prevent recurrent attacks.

Understanding Anti-Hyaluronidase

• Anti-hyaluronidase is an antibody produced against streptococcal hyaluronidase, one of several extracellular enzymes secreted by group A Streptococcus. 1
• Elevated anti-hyaluronidase titers serve as serologic evidence of recent streptococcal infection, similar to anti-streptolysin O (ASO) titers. 1
• These antibody tests help confirm preceding streptococcal infection when throat cultures are negative at the time of acute rheumatic fever presentation, which occurs in at least one-third of cases because the pharyngitis may have been subclinical or resolved weeks earlier. 1, 2

Actual Treatment of Acute Rheumatic Fever

Initial Antibiotic Eradication

• A full therapeutic course of penicillin must be given to all patients with acute rheumatic fever to eradicate residual group A Streptococcus, even if throat culture is negative at diagnosis. 1
• Penicillin V 250 mg 2–3 times daily for children <27 kg or 500 mg 2–3 times daily for children ≥27 kg, administered for 10 days. 1
• Alternatively, a single intramuscular dose of benzathine penicillin G 600,000 units (<27 kg) or 1.2 million units (≥27 kg) ensures complete eradication and eliminates adherence concerns. 1

Anti-Inflammatory Therapy

• High-dose salicylates (aspirin) remain the cornerstone for treating arthritis and mild carditis in acute rheumatic fever. 3
• Adrenal corticosteroids are reserved for severe carditis with heart failure. 3
• Treatment duration is guided by resolution of clinical and laboratory signs of inflammation. 3

Secondary Prophylaxis (Long-Term Prevention)

• Continuous antimicrobial prophylaxis provides the most effective protection from rheumatic fever recurrences and is mandatory for all patients with documented acute rheumatic fever. 1

• Duration depends on the presence and severity of cardiac involvement:

  • Rheumatic fever with carditis and residual valvular disease: 10 years or until age 40 (whichever is longer), sometimes lifelong. 1
  • Rheumatic fever with carditis but no residual valvular disease: 10 years or until age 21 (whichever is longer). 1
  • Rheumatic fever without carditis: 5 years or until age 21 (whichever is longer). 1

• Preferred secondary prophylaxis regimen: Benzathine penicillin G 1.2 million units intramuscularly every 3–4 weeks. 1

• Oral alternatives include penicillin V 250 mg twice daily or sulfadiazine 0.5 g once daily (<27 kg) or 1 g once daily (≥27 kg) for penicillin-allergic patients. 1

Common Pitfalls to Avoid

• Do not confuse serologic testing (anti-hyaluronidase, ASO titers) with treatment—these are diagnostic tools to document preceding streptococcal infection, not therapeutic interventions. 1
• Do not omit the initial 10-day penicillin course even when throat culture is negative at the time of acute rheumatic fever diagnosis, because residual streptococci may still be present. 1
• Do not delay or discontinue secondary prophylaxis prematurely, as recurrent streptococcal infections in patients with prior acute rheumatic fever carry a high risk of worsening cardiac damage. 1, 4
• Recognize that at least one-third of acute rheumatic fever cases result from inapparent (asymptomatic) streptococcal infections, underscoring the importance of continuous prophylaxis rather than relying solely on treating symptomatic pharyngitis. 1, 5

Risk Factors and Epidemiology

• Acute rheumatic fever predominantly affects children aged 5–15 years, with an incidence of 8–51 per 100,000 globally. 4
• Overcrowding, poor socioeconomic conditions, and inadequate medical care are directly proportional to acute rheumatic fever incidence. 4, 3
• Timely antibiotic treatment of group A streptococcal pharyngitis can prevent initial attacks of acute rheumatic fever, but prevention of recurrent attacks through continuous prophylaxis is the most effective strategy to prevent rheumatic heart disease. 4, 6